Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 11549296)

1.

The quest for the ideal stent.

de Feyter PJ.

Eur Heart J. 2001 Oct;22(19):1766-8. No abstract available.

2.

Heparin-coated stent and heparin-induced thrombocytopenia: true, true, and conceivably related.

Bittl JA.

Catheter Cardiovasc Interv. 2003 Jan;58(1):84-5. No abstract available.

PMID:
12508204
3.

Subacute stent thrombosis associated with a heparin-coated stent and heparin-induced thrombocytopenia.

Cruz D, Karlsberg R, Takano Y, Vora D, Tobis J.

Catheter Cardiovasc Interv. 2003 Jan;58(1):80-3.

PMID:
12508203
4.

Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, real world registry.

Gupta V, Aravamuthan BR, Baskerville S, Smith SK, Gupta V, Lauer MA, Fischell TA.

J Invasive Cardiol. 2004 Jun;16(6):304-10.

PMID:
15155999
5.

A stent is not just a stent: Stent construction and design do matter in its clinical performance.

Lau KW, Johan A, Sigwart U, Hung JS.

Singapore Med J. 2004 Jul;45(7):305-11; quiz 312. Review.

6.
7.

Randomized comparative study of diamond-like carbon coated stainless steel stent versus uncoated stent implantation in patients with coronary artery disease.

Meireles GC, de Abreu LM, Forte AA, Sumita MK, Sumita JH, Aliaga Jdel C.

Arq Bras Cardiol. 2007 Apr;88(4):390-5. English, Portuguese.

8.

Initial and follow-up results of the BiodivYsio phosphorylcholine coated stent for treatment of coronary artery disease.

Shinozaki N, Yokoi H, Iwabuchi M, Nosaka H, Kadota K, Mitsudo K, Nobuyoshi M.

Circ J. 2005 Mar;69(3):295-300.

9.

The role of BMS in the drug eluting stent era: is still there any place for them?

Fineschi M, Gori T.

Catheter Cardiovasc Interv. 2006 Sep;68(3):456; author reply 457. No abstract available.

PMID:
16892446
10.
11.
12.
13.

Heparin coating on ureteral Double J stents prevents encrustations: an in vivo case study.

Cauda F, Cauda V, Fiori C, Onida B, Garrone E.

J Endourol. 2008 Mar;22(3):465-72. doi: 10.1089/end.2007.0218.

PMID:
18307380
15.

Xience V everolimus-eluting coronary stent.

Kukreja N, Onuma Y, Serruys PW.

Expert Rev Med Devices. 2009 May;6(3):219-29. doi: 10.1586/erd.09.1. Review.

PMID:
19419279
16.

Stent fracture associated with drug-eluting stents: clinical characteristics and implications.

Lee MS, Jurewitz D, Aragon J, Forrester J, Makkar RR, Kar S.

Catheter Cardiovasc Interv. 2007 Feb 15;69(3):387-94.

PMID:
17195203
17.

Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy.

Waters RE, Kandzari DE, Phillips HR, Crawford LE, Sketch MH Jr.

Catheter Cardiovasc Interv. 2005 Aug;65(4):520-4.

PMID:
15973673
18.

The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured?

Beyar R, Roguin A.

Eur Heart J. 2001 Nov;22(22):2054-7. No abstract available.

19.

Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphorylcholine-coated coronary stent.

Grenadier E, Roguin A, Hertz I, Peled B, Boulos M, Nikolsky E, Amikam S, Kerner A, Cohen S, Beyar R.

Catheter Cardiovasc Interv. 2002 Mar;55(3):303-8.

PMID:
11870932
20.

Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation.

Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, Onuma Y, Higashikuni Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K.

Catheter Cardiovasc Interv. 2007 Feb 15;69(3):380-6.

PMID:
17195199
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk